HAT therapy for sepsis:A review of the therapeutic rationale and current clinical evaluation status  

作　　者：Yali Sun Yongfang Yang Zhuoyi Ye Tongwen Sun 

机构地区：[1]Department of General ICU,The First Affiliated Hospital of Zhengzhou University,Henan Key Laboratory of Critical Care Medicine,Zhengzhou Key Laboratory of Sepsis,Zhengzhou 450052,Henan,China [2]Henan Engineering Research Center for Critical Care Medicine,Department of General ICU,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,China

出　　处：《Journal of Intensive Medicine》2023年第4期320-325,共6页重症医学（英文）

基　　金：supported by the United Fund of the National Natural Science Foundation of China (grant number:U2004110);the National Natural Science Foundation of China (grant number:82172129);the Central Government Guides Local Science and Technology Development funds (grant number:Z20221343037);the Medical Science and Technology Tackling Plan Provincial and Ministerial Major Projects of Henan Province (grant number:SBGJ202101015);the special fund for young and middle-aged medical research of China International Medical Exchange Foundation (grant number:Z-2018-35);the integrated thinking research fund of China International Medical Exchange Foundation (grant number:Z-2016-23-2001).

摘　　要：Vitamin C-based cluster therapy,which involves the combined application of hydrocortisone,vitamin C,and thiamine(HAT),is a recently proposed new treatment option for sepsis on top of conventional treatment.This therapy has a strong theoretical basis,but its clinical efficacy remains inconclusive.This review summarizes the rationale for HAT therapy for sepsis and describes the evaluation of its efficacy in clinical observational studies and randomized controlled trials,with the aim of providing a reference for the future clinical practice application of HAT therapy in sepsis.

关 键 词：SEPSIS HAT therapy Hydrocortisone Vitamin C THIAMINE Metabolic resuscitation 

分 类 号：R631[医药卫生—外科学]